CD8+ Regulatory T Cell Deficiency in Elderly-Onset Rheumatoid Arthritis

被引:4
|
作者
Watanabe, Ryu [1 ]
Kadoba, Keiichiro [2 ]
Tamamoto, Atsuko [1 ]
Murata, Koichi [3 ,4 ]
Murakami, Kosaku [5 ]
Onizawa, Hideo [3 ]
Fujii, Takayuki [3 ,4 ]
Onishi, Akira [3 ]
Tanaka, Masao [3 ]
Ito, Hiromu [6 ]
Morinobu, Akio [2 ]
Hashimoto, Motomu [1 ]
机构
[1] Osaka Metropolitan Univ, Dept Clin Immunol, Grad Sch Med, Osaka 5458585, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Rheumatol & Clin Immunol, Kyoto 6068507, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Adv Med Rheumat Dis, Kyoto 6068507, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto 6068507, Japan
[5] Kyoto Univ, Ctr Canc Immunotherapy & Immunobiol, Grad Sch Med, Div Clin Immunol & Canc Immunotherapy, Kyoto 6068501, Japan
[6] Kurashiki Cent Hosp, Dept Orthopaed Surg, Kurashiki 7108602, Japan
关键词
CD8; elderly-onset; matrix metalloprotease-3; regulatory T cell; rheumatoid arthritis; SYSTEMIC-LUPUS-ERYTHEMATOSUS; LYMPHOCYTES; CLASSIFICATION; CD8(+)CD28(-); CRITERIA;
D O I
10.3390/jcm12062342
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Elderly-onset rheumatoid arthritis (EORA) is associated with higher disease activity and accelerated joint destruction compared with young-onset RA (YORA). However, the underlying immunological mechanism remains unclear. Regulatory T cells (Tregs) are an immunosuppressive T cell subset, and CD4(+) Tregs are deficient and/or dysfunctional in RA; however, CD8(+) Tregs have not been fully examined in RA. Here, we aimed to determine the role of CD8(+) Tregs, particularly in EORA. A total of 40 patients (EORA, n = 17; YORA, n = 23) were cross-sectionally enrolled. Current disease activity and treatment were comparable between the two groups; however, levels of multiple cytokines, including IL-1 beta, TNF alpha, interferon (IFN)-gamma, IL-2, and IL-10, were significantly increased in EORA. The number of CD4(+) Tregs did not differ between the groups (p = 0.37), but those of CD8(+) Tregs were significantly decreased in EORA (p = 0.0033). The number of CD8(+) Tregs were inversely correlated with plasma matrix metalloprotease (MMP)-3 levels (r = -0.3331, p = 0.036). Our study results revealed an intrinsic deficiency of CD8(+) Tregs in patients with EORA, which leaves synovitis unchecked with excessive MMP-3 release. A therapeutic approach to restore CD8(+) Tregs may provide a new avenue for the treatment of EORA.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Elderly-onset rheumatoid arthritis
    Yazici, Y
    Paget, SA
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2000, 26 (03) : 517 - +
  • [2] Elderly-onset rheumatoid arthritis
    Soubrier, Martin
    Mathieu, Sylvain
    Payet, Sarah
    Dubost, Jean-Jacques
    Ristori, Jean-Michel
    JOINT BONE SPINE, 2010, 77 (04) : 290 - 296
  • [3] ELDERLY-ONSET RHEUMATOID-ARTHRITIS
    VANSCHAARDENBURG, D
    BREEDVELD, FC
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 1994, 23 (06) : 367 - 378
  • [4] Mortality in elderly-onset rheumatoid arthritis (EORA).
    Mikuls, TR
    Cerhan, JR
    Merlino, L
    Moreland, LW
    Kaslow, R
    Criswell, LA
    Saag, KG
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S379 - S379
  • [5] TREATMENT OF ELDERLY-ONSET RHEUMATOID-ARTHRITIS
    SEWELL, KL
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1991, 39 (10) : 1043 - 1044
  • [6] Polymyalgia rheumatica and elderly-onset rheumatoid arthritis
    Shiozawa, S
    INTERNAL MEDICINE, 2002, 41 (08) : 605 - 605
  • [7] A Case of Painless Elderly-Onset Rheumatoid Arthritis
    Hayes, Oliver
    Haider, Sarkar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
  • [8] The clinical features of elderly-onset rheumatoid arthritis
    Rexhepi, S. K.
    Rexhepi, M. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 687 - 687
  • [9] Treatment of elderly-onset rheumatoid arthritis - review and recommendations
    Wollenhaupt, J
    Stichtenoth, DO
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 1999, 32 (02): : 168 - 168
  • [10] Management issues with elderly-onset rheumatoid arthritis - An update
    Olivieri, I
    Palazzi, C
    Peruz, G
    Padula, A
    DRUGS & AGING, 2005, 22 (10) : 809 - 822